Katsiki, N.; Vrablik, M.; Banach, M.; Gouni-Berthold, I. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals, 2023, 16(4), Art. No: 577. doi: 10.3390/ph16040577
DOI: https://doi.org/10.3390/ph16040577
Grundy, S.M.; Stone, N.J; Bailey, A.L.; Beam, C.; Birtcher K.K.; Blumenthal, R.S.; Braun, L.T.; De Feranti S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, A.E.; Peralta, C.A.; Saseen, J.J.; Smith Jr, S.C.; Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 139(25), e1082–e1143. doi: 10.1161/CIR.0000000000000625
DOI: https://doi.org/10.1161/CIR.0000000000000624
Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; Backer, G.G.D.; Delgado, V.; Ference,B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.’ Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R., Tokgozoglu, L.; Wiklund, O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J., 2019, 41(1), 111-188. doi: 10.1093/eurheartj/ehz455
DOI: https://doi.org/10.15829/1560-4071-2020-3826
Karagiannis, An.D.; Mehta, A.; Dhindsa, D.S; Virani, S.S.; Orringer, C.E.; Blumenthal, R.S.; Stone, N.J.; Sperling, L.S. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur. Heart J., 2021, 42(22), 2154-2169. doi: 10.1093/eurheartj/ehaa1080
DOI: https://doi.org/10.1093/eurheartj/ehaa1080
Soffer, D.; Stoekenbroek, R.; Plakogiannis, R. Small interfering ribonucleic acid for cholesterol lowering - inclisiran: inclisiran for cholesterol lowering. J. Clin. Lipidol., 2022, 16, 574–582. doi:10.1016/j.jacl.2022.06.009
DOI: https://doi.org/10.1016/j.jacl.2022.06.009
Goldstein, J.L.; Brown, M.S. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 2015, 161(1), 161-172. doi: 10.1016/j.cell.2015.01.036
DOI: https://doi.org/10.1016/j.cell.2015.01.036
Song, P.; Fang, Z.; Wang, H.; Cai, Y.; Rahimi, K.; Zhu, Y.; Fowkes, G.R.; Fowkes, F.J.; Rudan, I. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. The Lancet Glob. Health, 2020, 8(5), E721-E729. doi: 10.1016/S2214-109X(20)30117-0
DOI: https://doi.org/10.1016/S2214-109X(20)30117-0
Sopic, M.; Vilne, B.; Gerdts, E.; Trindade, F.; Uchida, S.; Khatib, S.; Wettinger, S.B.; Devaux, Y.; Magni, P. Multiomics tools for improved atherosclerotic cardiovascular disease management. Trends Mol. Med., 2023, 29(12), 983-995. doi: 10.1016/j.molmed.2023.09.004
DOI: https://doi.org/10.1016/j.molmed.2023.09.004
Patriki, D.; Saravi, S.S.S.; Camici, G.G.; Liberale, L.; Beer, J.H. PCSK 9: A Link Between Inflammation and Atherosclerosis. Curr. Med. Chem., 2021, 29(2), 251-267. doi: 10.2174/0929867328666210707192625
DOI: https://doi.org/10.2174/0929867328666210707192625
Nishikido, T. Clinical potencial of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc. Diabetol., 2023, 22, Art. No: 20. doi: 10.1186/s12933-023-01752-4
DOI: https://doi.org/10.1186/s12933-023-01752-4
Kallend, D.; Stoekenbroek, R.; He, Y.L.; Smith, P.F.; Wijngaard, P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J. Clin. Lipidol., 2022, 16(2), 208-219. doi: 10.1016/j.jacl.2022.01.001
DOI: https://doi.org/10.1016/j.jacl.2022.01.001
Wright, R.S.; Collins, M.G.; Stoekenbroek, R.M.; Robson, R.; Wijngaard, P.L.J.; Landmesser, U.; Leiter, L.A.; Kastelein, J.J.P.; Ray, K.K.; Kallend, D. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin. Proc., 2020, 95(1), 77-89. doi: 10.1016/j.mayocp.2019.08.021
DOI: https://doi.org/10.1016/j.mayocp.2019.08.021
Leiter, L.A.; Teoh, H.; Kallend, D.; Wright, S.; Landmesser, U.; Wijngaard, P.L.J.; Kastelein, J.J.P.; Ray, K.K. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care, 2019, 42(1), 173–176. doi: 10.2337/dc18-1491
DOI: https://doi.org/10.2337/dc18-1491
Ray, K.K.; Troguay, R.P.T.; Visseren, F.L.J.; Leiter, L.A.; Wright, S.; Vikarunnessa, S.; Talloczy, Z.; Zang, X.; Maheux, P.; Lesogor, A.; Landmesser, U. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol., 2023, 11(2), 109-119. doi: 10.1016/ S2213-8587(22)00353-9
DOI: https://doi.org/10.1016/S2213-8587(22)00353-9
Hovingh, G.K.; Lepor, N.E.; Kallend, D.; Stoekenbroek, R.M.; Wijngaard, P.; Raal, F.J. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation, 2020, 141(22), 1829-1831. doi: 10.1161/CIRCULATIONAHA.119.044431
DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.044431
Raal, F.; Durst, R.; Bi, R.; Talloczy, Z.; Maheux, P.; Lesogor, A.; Kastelein, J.J.P. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation, 2024, 149(5), 354-362. doi: 10.1161/CIRCULATIONAHA.122.063460
DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.063460
Raal, F.; Kallend, D.; Ray, K.K.; Turner, T.; Koenig, W.; Wright, S.; Wijngaard, P.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Kastelein, J.J.P. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N. Engl. J. Med., 2020, 382(16), 1520-1530. doi: 10.1056/NEJMoa1913805
DOI: https://doi.org/10.1056/NEJMoa1913805
Ray, K.K.; Phil, M.; Wright, S.; Kallend, D.; Koenig, W.; Leiter, L.A.; Raal, F.J.; Bisch, J.A.; Richardson, T.; Jaros, M.; Wijngaard, P.; Kastelein, J.J.P. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med., 2020, 382(16), 1507-1519. doi: 10.1056/NEJMoa1912387
DOI: https://doi.org/10.1056/NEJMoa1912387
Wright, S.; Ray, K.K.; Raal, F.J.; Kallend, D.G.; Jaros, M.; Koenig, W.; Leiter, L.A.; Landmesser, U.; Schwartz, G.G.; Friedman, A. Wijngaard, P.; Garcia Conde, L.; Kastelein, J.J.P. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J. Am. Coll. Cardiol., 2021, 77(9), 1182-1193. doi: 10.1016/j.jacc.2020.12.058
DOI: https://doi.org/10.1016/j.jacc.2020.12.058
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C (ORION-8). Available online: https://clinicaltrials.gov/study/NCT03814187 (accessed on 25.06.2024).
HPS-4 TIMI 65 ORION-4. Available online: https://www.orion4trial.org/homepage-uk (accessed on 26.06.2024).
Obwieszczenie Ministra Zdrowia z dnia 20 października 2022 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 listopada 2022 r. Available online: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia--20-pazdziernika-2022-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-listopada-2022-r. (accessed on 27.06.2024).
English
Język Polski
